These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy. Wright M; Hill S; Slaney MA Med J Aust; 1994 Jan; 160(1):45. PubMed ID: 8123141 [No Abstract] [Full Text] [Related]
3. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Wilson DK; Petrash M; Quiocho FA Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955 [TBL] [Abstract][Full Text] [Related]
4. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy. Florkowski CM Med J Aust; 1993 Nov; 159(10):711-2. PubMed ID: 8110237 [No Abstract] [Full Text] [Related]
5. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)]. Christensen JE; Larsen AB; Gregersen G Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975 [No Abstract] [Full Text] [Related]
6. New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N Biomed Pharmacother; 1995; 49(5):232-43. PubMed ID: 7579002 [No Abstract] [Full Text] [Related]
8. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy. Yue DK; Brooks B Med J Aust; 1993 Jul; 159(2):76-8. PubMed ID: 8336605 [No Abstract] [Full Text] [Related]
9. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications]. Hotta N; Sakamoto N Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677 [No Abstract] [Full Text] [Related]
10. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine. Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319 [TBL] [Abstract][Full Text] [Related]
11. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics. Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345 [No Abstract] [Full Text] [Related]
12. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]. Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304 [TBL] [Abstract][Full Text] [Related]
13. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. Schemmel KE; Padiyara RS; D'Souza JJ J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287 [TBL] [Abstract][Full Text] [Related]
16. [Significance of aldose-reductase inhibition with traditional Chinese and Western drugs in the treatment of diabetic peripheral neuropathy]. Liang X; Guo S Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 Jul; 19(7):442-4. PubMed ID: 11783220 [No Abstract] [Full Text] [Related]
18. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. Baba M; Kimura K; Suda T; Yagihashi S; J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519 [No Abstract] [Full Text] [Related]